Alpha 37 / Nordic Nanovector, Orano - LARVOL DELTA

Targeted alpha therapy with 212Pb-NNV003 in treatment of NHL (AACR 2022) - "Standard of care includes chemotherapy combined with anti-CD20 antibodies (obinutuzumab and rituximab) and Bruton’s tyrosine kinase inhibitor ibrutinib...212Pb-cetuximab (unspecific isotype control), unlabelled NNV003 and NaCl were used as controls. In vitro testing of the antibody showed that MEC-2 cells were 5 times more resistant to ibrutinib than Daudi cells... The study shows that a single injection 212Pb-NNV003 is safe and effective for the treatment of CD37 positive CLL and NHL in preclinical models, with promising efficacy in both ibrutinib-resistant and sensitive CLL models. Treatment with 212Pb-NNV003 was superior to both ibrutinib and obinutuzumab. Further clinical testing is warranted."

Burkitt Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting (PRNewswire) - “Nordic Nanovector ASA…announces that an E-poster regarding Alpha37, entitled 'Targeted alpha therapy with 212Pb-NNV003 in treatment of NHL', will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA.”

Preclinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

"#NordicNanovector Announces EU Patent Granted Covering the Use of #Alpha37 $NANO https://t.co/mQFlOHyRJp" (@1stOncology)

Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37 (PRNewswire) - "Nordic Nanovector ASA...is pleased to announce the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212....EU patent no. 3272364, which is entitled 'Chimeric Therapeutic Antibodies' will be active until 2032 with the option of prolonging for five 5 additional years."

Patent • Chronic Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology